Highest-materiality recent filing
Inhibikase Q1 2026 net loss $16.4M; first patient enrolled in Phase 3 PAH study IMPROVE-PAH
Net loss $16.4M ($0.10 EPS) vs $13.7M ($0.15) in Q1 2025; cash & equivalents $170.4M as of Mar 31, 2026.
Inhibikase enrolls first patient in Phase 3 PAH study of IKT-001
First patient enrolled in global pivotal Phase 3 IMPROVE-PAH trial (NCT07365332).
Inhibikase reports FY2025 net loss $48.3M; advances IKT-001 into Phase 3 PAH trial
Net loss of $48.3M ($0.49/share) for FY2025 vs $27.5M ($1.16/share) in FY2024.
Inhibikase raises ~$93.6M in public offering, advances IKT-001 to Phase 3 PAH trial
Offering of 46.1M shares at $1.45/share and pre-funded warrants for 22.9M shares; net proceeds ~$93.6M.
IKT advances IKT-001 to global pivotal Phase 3 in PAH; ATM prospectus terminated
IMPROVE-PAH Phase 3 trial for IKT-001 in pulmonary arterial hypertension expected to start Q1 2026 across up to 180 sites.
Inhibikase Q3 net loss $11.9M ($0.13/sh); advancing IKT-001 Ph2b in PAH
Net loss $11.9M for Q3 2025 vs $5.8M YoY; cash $77.3M at Sep 30, down from $97.5M at Dec 2024.
Inhibikase Q2 net loss $9.9M; Phase 2b IKT-001 PAH trial to start H2 2025
Cash and marketable securities $87.7M at June 30, 2025, vs $97.5M at Dec 31, 2024.
Inhibikase Q1 net loss $13.7M; advancing IKT-001 PAH Ph2b trial in H2 2025
Net loss $13.7M ($0.15/share) vs $4.6M ($0.73) in Q1 2024; includes $7.4M non-cash acquisition charge for CorHepta.
Inhibikase Therapeutics appoints David McIntyre as CFO as Garth Lees-Rolfe resigns
Garth Lees-Rolfe resigned as CFO effective April 11, 2025; not due to any dispute with the Company.
Inhibikase reports 2024 net loss $27.5M; cash $97.5M; PAH trial progress, new leadership
Net loss $27.5M ($1.16 per share) vs $19.1M ($3.16 per share) in 2023; R&D $17.2M, SG&A $11.4M.
Inhibikase acquires CorHepta for $15M in stock; appoints Cabell as President and Adams as CSO
Acquired CorHepta for $15M in stock: 4,979,101 shares issued (3,319,397 upfront, remainder contingent on milestone).
Inhibikase appoints Mark Iwicki as CEO; founder Milton Werner resigns
Milton Werner resigned as CEO/board member effective Feb 13, 2025; will consult through May 13, 2025 at $44,583/month.
Inhibikase Phase 2 risvodetinib trial misses primary efficacy endpoint; development paused
Trial enrolled 126 untreated Parkinson's patients; 95% completed 12 weeks with safety comparable to placebo.
Inhibikase shareholders approve 5x authorized share increase to 500M and option repricing
Stockholders approved increase in authorized common shares from 100M to 500M; Certificate of Amendment filed Jan 3, 2025.
Inhibikase closes $110M private placement, up to $275M total, advances IkT-001Pro in PAH
Gross proceeds ~$110M from private placement; potential aggregate up to ~$275M from warrant exercises.
Inhibikase raises ~$110M in private placement; appoints four new directors
Gross proceeds ~$110M from common stock, pre-funded warrants, and Series A-1/B-1 warrants at $1.37 per share unit.
Inhibikase raises $4.0M in registered direct offering and warrant inducement
Offering of 1,672,452 shares (or pre-funded warrants) at $1.68/unit with Series A and B warrants.
Inhibikase receives arbitration demand for $1.625M from Pivot over milestone payments
Pivot Holding LLC, successor to Sphaera Pharma, demands $1.625 million plus interest for alleged breach of 2012 collaboration agreement.
Inhibikase 201 trial ~75% enrolled; expects completion by mid-June 2024
201 Trial (risvodetinib) ~75% enrolled, 30 patients left; enrollment completion expected mid-June 2024.
FDA pre-NDA meeting on Jan 19, 2024: acknowledges 505(b)(2) pathway appropriate for IkT-001Pro in blood/gastrointestinal cancers.
Inhibikase CFO Joseph Frattaroli to retire; Garth Lees-Rolfe promoted as successor
Joseph Frattaroli to retire as CFO effective March 31, 2024; vested stock option exercise period extended.
Inhibikase provides pipeline updates after sharp stock decline; 201 Trial enrollment at 28 patients
Stock dropped dramatically over last 8 trading sessions; no identifiable cause for volatility.
Inhibikase Therapeutics announces 1-for-6 reverse stock split to regain Nasdaq compliance
Reverse stock split effective June 30, 2023; shares outstanding reduced from ~31.6M to ~5.3M.
Inhibikase raises ~$10M via registered direct offering and private placement with warrants
Offering includes 6,744,187 shares/equivalents at $0.86/share in registered direct, plus 4,883,721 in private placement.
FDA lifts full clinical hold on Inhibikase's IkT-148009 for Parkinson's; Phase 2a trial restarting
FDA lifted full clinical hold on IkT-148009; Phase 2a 201 trial resumes at 50 and 100 mg doses.
Inhibikase Q3 net loss $4.49M; FDA clinical hold on IkT-148009 programs
Q3 2022 net loss of $4.49M ($0.18 per share) vs. $4.47M in Q3 2021.
FDA imposes clinical hold on Inhibikase's IkT-148009 Parkinson's and MSA programs
FDA placed a clinical hold on the IkT-148009 201 program in Parkinson's disease and its use in Multiple Systems Atrophy (MSA).
Inhibikase Therapeutics presents Phase 1/1b data for IkT-148009 in Parkinson's; Phase 2 ongoing
Phase 1/1b of IkT-148009 (88 healthy, 13 PD patients) showed no clinically significant AEs, linear PK, and CNS penetration over 12.5-325 mg daily doses.
Inhibikase receives Nasdaq notice for non-compliance with $1.00 minimum bid price rule
Nasdaq notice dated July 25, 2022; stock bid price below $1.00 for 30 consecutive business days.
Aggregate offering price up to $9,801,287 of common stock; sales at market prices via Piper Sandler.
Effective April 14, 2025, the Board appointed David McIntyre as Chief Financial Officer, principal financial officer and principal accounting officer of the Company (the “Appointment”).
Effective April 11, 2025, Garth Lees-Rolfe resigned as Chief Financial Officer, principal financial officer and principal accounting officer of Inhibikase Therapeutics, Inc. (the “Company”).
The Board also expanded its size from seven to eight directors and appointed Vincent Aurentz to serve as a Class I director of the Board.
the Board appointed Chris Cabell as President and Head of Research and Development of the Company.
Effective February 13, 2025, Milton H. Werner, Ph.D. resigned as President, Chief Executive Officer and principal executive officer of Inhibikase Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company (the “Resignation”).
Effective February 14, 2025, the Board appointed Mark Iwicki as President, Chief Executive Officer and principal executive officer of the Company (the “Appointment”).
the Board appointed Roberto Bellini to serve as a Class I director of the Board
The Board has elected Mr. Bellini as independent Chairperson of the Board.
Arvind Kush to serve as a Class III director of the Board
Dr. Paul Grint and Ms. Gisele Dion (the " Resigning Directors ") became effective as of the effectiveness of the appointment of their respective successors.
Amit Munshi and David Canner to serve as Class II directors of the Board
Dr. Paul Grint and Ms. Gisele Dion (the " Resigning Directors ") became effective as of the effectiveness of the appointment of their respective successors.
Max materiality 0.90 · Median 0.60 · Most common event other_material